Trial ID or NCT#
NCT02576548
Status
Purpose
This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
Official Title
A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors
Eligibility Criteria
Ages Eligible for Study: 18 Years to 99 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Melinda L. Telli, M.D.
Medical oncologist,
Breast specialist
Associate Professor of Medicine (Oncology)
Contact us to find out if this trial is right for you.
CONTACT
CCTO
(650) 498-7061
View on ClinicalTrials.gov